Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

13.27 -0.21 (-1.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
HUTCHMED Cancer Med Cuts Death Risk By 34% In Metastatic Colorectal Cancer
Via Benzinga
7 Chinese Stocks to Sell While You Still Can
These Chinese stocks have had a rough outing at the stock markets of late, as their underlying businesses buckle under the economic pressure 
Via InvestorPlace
Week in Review: Hansoh In-licenses Endometriosis/Fibroid Therapy in $170 Million Deal
Other funding deals for drug discovery, R&D, gene editing. 
Via Talk Markets
Recap of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Goldman Sachs Maintains Neutral Rating for HUTCHMED: Here's What You Need To Know
  Goldman Sachs has decided to maintain its Neutral rating of HUTCHMED (China) (NASDAQ:HCM) and raise its price target from $14.00 to $16.00. Shares of HUTCHMED (China) are trading down 5.74% over the... 
Via Benzinga
Recap of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting
Via Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: FDA Signs Off Cancer Therapy Trials For NexImmune, Omega Therapeutics, Endo To Develop Rare Hereditary Skin Disease Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
HUTCHMED Highlights SAVANNAH Trial Data Of Savolitinib Combo In Lung Cancer Setting
Via Benzinga
83 Biggest Movers From Yesterday
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
HUTCHMED (China) Limited (NASDAQ:HCM) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 06/08/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at HUTCHMED (China) Limited. 
Via SBWire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in HUTCHMED (China) Limited with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in HUTCHMED (China) Limited with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages HUTCHMED (China) Limited Investors with Losses to Inquire About Class Action Investigation – HCM
From The Rosen Law Firm, P.A.
Via Business Wire
38 Stocks Moving In Friday's Mid-Day Session
Gainers Leju Holdings Limited (NYSE: LEJU) surged 27.8% to $4.0413. 
Via Benzinga
20 Stocks Moving in Friday's Pre-Market Session
Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 28.1% to $0.1550 in pre-market trading. Exicure said in Form4 filing a director bought 1,472,126 shares at average price of $0.19 per share. 
Via Benzinga
76 Biggest Movers From Yesterday
Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to... 
Via Benzinga
NASDAQ:HCM Shareholder Notice: Investigation over Possible Securities Laws Violations by HUTCHMED (China) Limited
San Diego, CA -- (SBWIRE) -- 05/16/2022 -- HUTCHMED (China) Limited is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The... 
Via Benzinga
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in... 
Via Talk Markets
66 Biggest Movers From Yesterday
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... 
Via Benzinga
HFCAA News: 128 Chinese Stocks the SEC Could Delist
The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
31 Stocks Moving In Monday's Mid-Day Session
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition. SoundHound AI, Inc. (NASDAQ: SOUN) shares gained 30.5% to $8.48... 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Lower; US Factory Growth Slows In April
U.S. stocks traded mostly lower this morning, with the Dow Jones tumbling around 100 points on Monday. 
Via Benzinga
U.S. FDA Rejects HUTCHMED's New Drug Application For Surufatinib In Neuroendocrine Tumors
HUTCHMED (China) Limited (Nasdaq: HCM) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for Surufatinib for the treatment of... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS